Vofatamab
- Generic Name
- Vofatamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1312305-12-6
- Unique Ingredient Identifier
- JMH6YR91PG
- Background
Vofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Rainier Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT02401542
- Locations
- 🇬🇧
Research Site, Preston, United Kingdom
🇺🇸Reaserach Site, Fort Wayne, Indiana, United States
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01363024
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01122875
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath